AngioDynamics, Inc. (NASDAQ:ANGO) Receives Average Rating of “Moderate Buy” from Analysts

AngioDynamics, Inc. (NASDAQ:ANGO) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $19.3333.

A number of research analysts have recently issued reports on ANGO shares. Zacks Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, January 21st. Finally, Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its position in AngioDynamics by 9.6% in the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock worth $2,434,000 after buying an additional 22,658 shares during the period. Jane Street Group LLC boosted its holdings in shares of AngioDynamics by 267.1% during the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after acquiring an additional 34,054 shares during the period. Bastion Asset Management Inc. increased its holdings in shares of AngioDynamics by 46.5% in the 2nd quarter. Bastion Asset Management Inc. now owns 959,043 shares of the medical instruments supplier’s stock worth $9,810,000 after acquiring an additional 304,217 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of AngioDynamics in the 2nd quarter worth about $139,000. Finally, Integrated Quantitative Investments LLC bought a new stake in AngioDynamics in the 2nd quarter valued at about $241,000. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Trading Down 0.4%

ANGO stock opened at $10.83 on Wednesday. The stock’s 50 day simple moving average is $11.00 and its 200 day simple moving average is $11.49. AngioDynamics has a 12-month low of $8.27 and a 12-month high of $13.99. The firm has a market cap of $446.41 million, a P/E ratio of -16.16 and a beta of 0.48.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.